Terrin, Alberto
Bello, Luca
Valentino, Maria Lucia
Caporali, Leonardo
SorarĂ¹, Gianni
Carelli, Valerio
Maggioni, Ferdinando
Zeviani, Massimo
Pegoraro, Elena http://orcid.org/0000-0002-7740-4156
Article History
Received: 30 October 2021
Accepted: 4 March 2022
First Online: 10 March 2022
Competing interests
: Elena Pegoraro reports a study grant from Santhera, consulting honoraria from Sarepta, Roche, Alexion, UCB Biopharma, Epirium, Biogen and travel grants from Genzyme. Luca Bello reports speaker honoraria from PTC Therapeutics, and participation in advisory boards for Sarepta, Edgewise, Epirium, and PTC Therapeutics. Alberto Terrin, Ferdinando Maggioni, Maria Lucia Valentino, Leonardo Caporali, Gianni SorarĂ¹ and Massimo Zeviani have no relevant financial or non-financial interests to disclose. Valerio Carelli reports consulting honoraria from Chiesi Farmaceutici, GenSight Biologics, and Stealth Biotherapeutics. Valerio Carelli is supported by the Italian Ministry of Health (Ricerca Corrrente funding).